The HealthCare unit of
) received encouraging news from the US Food and Drug
Administration (FDA), which recently approved Bayer's low dose
levonorgestrel-releasing intrauterine system (IUS) known as
Skyla. Skyla helps in preventing pregnancy for up to three years
when placed in the uterus.
Skyla's approval provides women with a reliable option in case
they want to avoid taking pills. Moreover, the new IUS allows a
rapid return to a women's usual level of fertility after removal.
Skyla's approval will add on to Bayer's wide range of birth
Meanwhile, in Dec 2012, Bayer successfully completed its
registration procedure in the EU for its new IUS system. The
product is expected to be marketed in the EU under the trade name
We note that companies like
) have a presence in the birth control products market.
The HealthCare unit of Bayer was recently in the news for
receiving the necessary regulatory approval from the Federal
Trade Commission for the completion of its acquisition of
Teva Pharmaceutical Industries Limited
) animal health unit in the US.
Moreover, the HealthCare unit of Bayer announced earlier this
month that a phase III trial (DECISION: n=417) of Nexavar
(sorafenib), co-developed and marketed with
Onyx Pharmaceuticals Inc.
) met its primary endpoint.
We currently have a Neutral recommendation on Bayer. The stock
carries a Zacks Rank #2 (Buy). Other large-cap pharma stocks such
Eli Lilly and Company
) also carry a Zacks #2 Rank (Buy).
BAYER A G -ADR (BAYRY): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
ONYX PHARMA INC (ONXX): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
WARNER CHIL PLC (WCRX): Free Stock Analysis
To read this article on Zacks.com click here.